Rodin Therapeutics Inc. announced a private placement of preferred shares for gross proceeds of $17,300,000 on January 6, 2016. The transaction included participation from returning investor, Atlas Venture L.P. and new investor Biogen Inc. As part of the round, Samantha Budd Haeberlein of Biogen Inc. will join the company's board of directors.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
221.6 USD | -3.69% |
|
-2.85% | -14.37% |
12:26pm | Goldman Sachs Adjusts Price Target on Biogen to $342 From $340, Maintains Buy Rating | MT |
09:00am | Novo owner backs Swiss biotech Asceneuron in $100 million round | RE |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.37% | 32.26B | |
+7.40% | 101B | |
+7.76% | 42.18B | |
+80.35% | 29.79B | |
-12.27% | 16.06B | |
+2.33% | 14.45B | |
-8.56% | 12.01B | |
+182.74% | 10.71B | |
+4.04% | 8.89B | |
-56.23% | 8.83B |
- Stock Market
- Equities
- BIIB Stock
- News Biogen Inc.
- Rodin Therapeutics Inc. announced that it expects to receive $17.3 million in funding from Biogen Inc., Atlas Venture L.P.